Salient Capital Advisors’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
Sell
-86,138
Closed -$11.4M 126
2017
Q2
$11.4M Sell
86,138
-1,806
-2% -$230K 0.22% 43
2017
Q1
$11M Buy
87,944
+4,473
+5% +$534K 0.2% 44
2016
Q4
$9.62M Buy
83,471
+4,536
+6% +$524K 0.18% 41
2016
Q3
$9.32M Sell
78,935
-6,410
-8% -$778K 0.19% 47
2016
Q2
$10.4M Sell
85,345
-3,573
-4% -$406K 0.23% 45
2016
Q1
$9.62M Buy
88,918
+1,846
+2% +$191K 0.27% 49
2015
Q4
$8.94M Buy
87,072
+14,145
+19% +$1.42M 0.24% 52
2015
Q3
$6.81M Sell
72,927
-8,791
-11% -$850K 0.17% 63
2015
Q2
$7.96M Buy
81,718
+16,214
+25% +$1.62M 0.15% 65
2015
Q1
$6.59M Buy
65,504
+7,390
+13% +$752K 0.12% 68
2014
Q4
$6.08M Buy
58,114
+15,758
+37% +$1.66M 0.12% 69
2014
Q3
$4.51M Buy
42,356
+6,765
+19% +$702K 0.08% 86
2014
Q2
$3.72M Buy
35,591
+2,505
+8% +$253K 0.08% 80
2014
Q1
$3.25M Buy
33,086
+16,230
+96% +$1.5M 0.09% 76
2013
Q4
$1.54M Buy
16,856
+9,310
+123% +$858K 0.05% 104
2013
Q3
$654K Sell
7,546
-1,625
-18% -$146K 0.03% 113
2013
Q2
$787K Buy
+9,171
New +$778K 0.04% 106

Other funds holding JNJ

Salient Capital Advisors's JNJ Position: Q3 2017 in Review

Salient Capital Advisors sold out of Johnson & Johnson (JNJ) in Q3 2017, closing a stake of 86,138 shares — an estimated $11.4M sold.

Salient Capital Advisors first reported a position in JNJ in Q2 2013 and held it in 17 quarters. The position peaked at $11.4M in Q2 2017. 2,356 funds tracked by Wall St. Rank hold JNJ as of Q3 2017.

  • Salient Capital Advisors reported no remaining Johnson & Johnson position as of Q3 2017 after selling out during the quarter.
  • Salient Capital Advisors sold 86,138 Johnson & Johnson shares in Q3 2017, an estimated $11.4M.
  • Salient Capital Advisors first reported a position in Johnson & Johnson in Q2 2013 and held it in 17 quarters.
  • Salient Capital Advisors's Johnson & Johnson position peaked at $11.4M in Q2 2017.
  • 2,356 funds tracked by Wall St. Rank held Johnson & Johnson as of Q3 2017.

Based on Salient Capital Advisors's 13F filing for Q3 2017, filed 6 Nov 2017.